ARTICLE | Clinical News

Achaogen reports Phase I data for antibacterial candidate C-Scape

January 12, 2018 5:29 PM UTC

Achaogen Inc. (NASDAQ:AKAO) reported top-line data from a Phase I in 41 healthy volunteers with and without renal impairment showing that antibacterial candidate C-Scape for 14 days was well tolerated with no serious adverse events reported. The most common adverse events reported included vascular access-site bruising, headache, diarrhea, gastroenteritis and nausea. The company is developing the oral combination of ceftibuten, a third-generation cephalosporin, and clavulanate, a beta lactamase (LACTB) inhibitor, to treat multi-drug resistant (MDR) gram-negative bacterial infections. The double-blind, placebo-controlled, Australian trial evaluated the safety and pharmacokinetics of C-Scape.

This year, Achaogen plans to start a Phase III trial of the product to treat complicated urinary tract infections (cUTIs)...

BCIQ Company Profiles

Achaogen Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)